chevron_leftBack
As of 14 June 2026, Atossa Therapeutics, Inc. has a market cap of $21.18M USD, ranking #36713 globally and #4969 in the United States.
It ranks #3296 in the Healthcare sector, and #1104 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$21.18MUSD
Enterprise Value
$5.98MUSD
EBITDA (TTM)
-$37.13MUSD
Net Income (TTM)
-$34.77MUSD
PB Ratio
1.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Steven Quay
open_in_new
Employees
16
Founded
2009
IPO
08 Nov 2012
Website
atossatherapeutics.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.8% | -11% | 12% | -43% | -62% | -53% |
News
Loading...
ATOS Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ATOS
ISIN: US04962H7044
Shares Out.:
Shares Outstanding:
8.611M1
Shares Float:
8.459M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
5.28 USD | |
|
ATOS
ISIN: US04962H7044
|
96.00 MXN | |
|
YAG2
Atossa Therapeutics Inc
ISIN: US04962H5063
|
0.5570 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
4M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
3M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
2M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
1M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
705K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
555K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
2M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
1M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
1M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
858K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
520K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
512K%
80.96B GBP
|
14.6
|
chevron_leftBack